This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
Deep Transcranial Magnetic Stimulation for treatment-resistant bipolar depression: A case report of acute and maintenance efficacy
Bersani, F. S., Girardi, N., Sanna, L., Mazzarini, L., Santucci, C., Kotzalidis, G. D., & Girardi, P. (2013). Neurocase, 19(5), 451-457.
This case report examines the effect of Brainsway® Deep TMS (Deep Transcranial Magnetic Stimulation) H-coil stimulation in a patient with bipolar depression. The patient was provided with 20 daily consecutive Transcranial Magnetic Stimulation sessions, as well as one session every 2 weeks, over 3 months after the initial treatment. In this patient, symptoms were significantly alleviated and cognition was significantly enhanced following treatment. Moreover, these beneficial effects were evident for 6 months post treatment.